Cost evaluation of adverse drug reactions in hospitalized patients in Taiwan: A prospective, descriptive, observational study

Current Therapeutic Research - Clinical and Experimental

Volumn 69, Issue 2, 2008, Pages 118-129

  Chan, Agnes L F ^a,b   Lee, Haw Yu ^a   Ho, Chi Hou ^a   Cham, Thau Ming ^b   Lin, Shun Jin ^b  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

adverse drug reactions; direct medical cost

Indexed keywords

ALLOPURINOL; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; ANTIGOUT AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIPYRETIC AGENT; ANTITHROMBOCYTIC AGENT; CARDIOVASCULAR AGENT; CEFAZOLIN; CENTRAL NERVOUS SYSTEM AGENTS; DERMATOLOGICAL AGENT; GASTROINTESTINAL AGENT; HORMONE; MUSCLE RELAXANT AGENT; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; RESPIRATORY TRACT AGENT; STEROID; TUBERCULOSTATIC AGENT;

AGED; ALGORITHM; ANAPHYLAXIS; ARTICLE; BLEEDING; BRADYCARDIA; CALCULATION; DIARRHEA; DISEASE SEVERITY; DRUG OVERDOSE; EMERGENCY WARD; FEMALE; HOSPITAL ADMISSION; HOSPITAL COST; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INCIDENCE; INJECTION SITE RASH; INTENSIVE CARE UNIT; LABORATORY TEST; LENGTH OF STAY; MALE; MEDICAL FEE; MONITORING; NEUTROPENIA; NURSE; OBSERVATIONAL STUDY; PHARMACIST; PHYSICIAN; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; RASH; STEVENS JOHNSON SYNDROME; TAIWAN; TEACHING HOSPITAL; THROMBOCYTOPENIA; TREMOR; VOMITING; WORLD HEALTH ORGANIZATION;

EID: 45149121962     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curtheres.2008.04.005     Document Type: Article

References (27)

1. Lazarou J., Pomeranz B., and Corey P. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 279 (1998) 1200-1205
2. Bates D. Drugs and adverse drug reactions. How worried should we be?. JAMA 279 (1998) 1216-1217
3. Beijer H., and de Blaey C. Hospitalizations caused by adverse drug reactions (ADR): A meta-analysis of observational studies. Pharm World Sci 24 (2002) 46-54
4. Pirmohamed M., James S., Meakin S., et al. Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18 820 patients. BMJ 329 (2004) 15-19
5. Onder G., Pedone C., Landi F., et al. Adverse drug reactions as cause of hospital admissions: Results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA). J Am Geriatr Soc 50 (2002) 1962-1968
6. Johnson J., and Bootman J. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med 155 (1995) 1949-1956
7. White T., Arakelian A., and Rho J. Counting the costs of drug-related adverse events. Pharmaco-Economics 15 (1999) 445-458
8. World Health Organization. Collaborating Centers for International Drug Monitoring (1984), World Health Organization, Geneva, Switzerland WHO publication DEM/NC/84.153(E)
9. Wang H., Chen H., and Hung Y. The value of community: Prevention of infectious disease. Presented at: The National Taiwan University Post-SAR Conference (January 2, 2004) Taipei, Taiwan
10. Nita Y., Plumridge R., and Batty K. Adverse drug reaction reporting in Australian Hospitals. Int J Pharm Pract 12 (2004) 155-161
11. Naranjo C., Busto U., Sellers E., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30 (1981) 239-245
12. Hartwig S., Siegel J., and Schneider P. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 49 (1992) 2229-2232
13. Rawlins M., and Thompson J. Pathogenesis of adverse drug reactions. In: Davies D. (Ed). Textbook of Adverse Drug Reactions (1977), Oxford University Press, Oxford, United Kingdom 10
14. Murphy B., and Frigo L. Development, implementation, and results of a successful multidisciplinary adverse drug reaction reporting program in a university teaching hospital. Hosp Pharm 28 (1993) 1199-1204
15. Murphy B., and Frigo L. Development, implementation, and results of a successful multidisciplinary adverse drug reaction reporting program in a university teaching hospital. Hosp Pharm 28 (1993) 1199-1240
16. Bennett B., and Lipman A. Comparative study of prospective surveillance and voluntary reporting in determining the incidence of adverse drug reactions. Am J Hosp Pharm 34 (1977) 931-936
17. Keith M., Bellanger McCleery R., and Fuchs Jr. J. Multidisciplinary program for detecting and evaluating adverse drug reactions. Am J Hosp Pharm 46 (1989) 1809-1812
18. Williamson J., and Chopin J. Adverse reactions to prescribed drugs in the elderly: A multicenter investigation. Age Ageing 9 (1980) 73-80
19. Carbonin P., Pahor M., Bernabei R., et al. Is age an independent risk factor of adverse drug reactions in hospitalized medical patients?. J Am Geriatr Soc 39 (1991) 1093-1099
20. van der Hooft C., Sturkenboom M., van Grootheest K., et al. Adverse drug reaction-related hospitalizations: A nationwide study in The Netherlands. Drug Saf 29 (2006) 161-168
21. Ramesh M., Pandit J., and Parthasarathi G. Adverse drug reactions in a South Indian hospital-their severity and cost involved. Pharmacoepidemiol Drug Saf 12 (2003) 687-692
22. Suh D., Woodall B., Shin S., and Hermes-De Santis E. Clinical and economic impact of adverse drug reactions in hospitalized patients. Ann Pharmacother 34 (2000) 1373-1379
23. Wolf R., Orion E., Marcos B., and Matz H. Life-threatening acute adverse cutaneous drug reactions. Clin Dermatol 23 (2005) 171-181
24. Bordet R., Gautier S., Le Louet H., et al. Analysis of the direct cost of adverse drug reactions in hospitalized patients. Eur J Clin Pharmacol 56 (2001) 935-941
25. Dormann H., Muth-Selbach U., Krebs S., et al. Incidence and costs of adverse drug reactions during hospitalization: Computerized monitoring versus stimulated spontaneous reporting. Drug Safety 22 (2000) 161-168
26. Classen D., Pestotnik S., Evans R., and Burke J. Computerized surveillance of adverse drug events in hospital patients. JAMA 266 (1991) 2847-2851
27. Prosser T., and Kamysz P. Multidisciplinary adverse drug reaction surveillance program. Am J Hosp Pharm 47 (1990) 1334-1339